Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8474067 | Journal of Molecular and Cellular Cardiology | 2015 | 13 Pages |
Abstract
In summary, we identified the C-terminal four amino-acid variable end of TB4 as the essential and responsible domain for the molecule's full benefits in the hypoxic heart. Additionally, we introduced AGES as a novel, systemically applicable drug candidate to aid cardiac infarction in adult mammals.
Keywords
PBSWT-1Connexin43PKCEDDCX43connexinsGAPDHACEAIVThymosin β15AARESDSca-1MPOSESMyocardial infarctionAngiotensin-converting enzymeILKleft ventricledrug researchTerminal deoxynucleotidyl transferase dUTP nick end labelingTUNELThymosin β10Thymosin beta-4injected doseVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Phosphate buffered salineLADarea at riskmyeloperoxidaseProtein kinase Cleft anterior descendingfractional shorteningintegrin-linked kinaseglyceraldehyde 3-phosphate dehydrogenase
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Rabea Hinkel, Haydn L. Ball, J. Michael DiMaio, Santwana Shrivastava, Jeffrey E. Thatcher, Ajay N. Singh, Xiankai Sun, Gabor Faskerti, Eric N. Olson, Christian Kupatt, Ildiko Bock-Marquette,